Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f9c7c3a9423077fcc1ad88cfeb92703e http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_50be7f835a15e20cbf1724b3367dd2dc http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d844dde5d51a70a576d39abe228d8b94 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2770-32032 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-165 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N7-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6893 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2866 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-768 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4745 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-553 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-768 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-74 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-36 |
filingDate |
2020-07-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2864744a9bea63262fce63a62b16424f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c359248f92512db6f5ade8898b41b3d2 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f205d2620929cb8056bbea8609c44f48 |
publicationDate |
2021-01-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
WO-2021016194-A1 |
titleOfInvention |
Second generation seneca valley virus oncolytic therapy: compositions and methods thereof |
abstract |
Provided herein are compositions and methods of using Seneca Valley Virus (SVV) or a derivative thereof and an interferon type I (IFN-I) inhibiting agent comprising an mTOR inhibitor for treating a cancer in a subject. The disclosed methods particularly rely upon the expression level of an ANTXR1 and the expression level of IFN-I in the cancer from the subject. Also provided herein are methods for predicting the efficacy of an SVV treatment comprising IFN-I inhibiting agent. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11738058-B2 |
priorityDate |
2019-07-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |